(Q50764332)

English

Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab.

scientific article published on 29 March 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

inflammatory bowel diseases

0 references

Edward L Barnes

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

author name string

Jessica R Allegretti

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Betsey Stevens

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Margaret Storm

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Ashwin Ananthakrishnan

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Vijay Yajnik

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Joshua Korzenik

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

publication date

29 March 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Digestive Diseases and Sciences

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

62

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1590-1596

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

https://scigraph.springernature.com/pub.10.1007/s10620-017-4549-3

0 references

The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Vedolizumab for the treatment of moderately to severely active ulcerative colitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Vedolizumab as induction and maintenance therapy for Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Vedolizumab as induction and maintenance therapy for ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Positioning biologic agents in the treatment of Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

A simple clinical colitis activity index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

A simple index of Crohn's-disease activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

14 August 2018

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

14 August 2018

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

14 August 2018

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4549-3

21 January 2018

The safety of vedolizumab for ulcerative colitis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4549-3

21 January 2018

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4549-3

21 January 2018

Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population

1 reference

https://pubmed.ncbi.nlm.nih.gov/28357697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10620-017-4549-3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50764332&oldid=1459851997"